Scleral lenses help manage OSD

Article

Commercially available scleral lenses can help manage moderate to severe ocular surface disease (OSD), according to new research out of the Mayo Clinic. As a bonus, the lenses can improve visual acuity (VA) in those whose vision has been negatively affected by the disease.

Commercially available scleral lenses can help manage moderate to severe ocular surface disease (OSD), according to new research out of the Mayo Clinic. As a bonus, the lenses can improve visual acuity (VA) in those whose vision has been negatively affected by the disease.

Diagnostic trial lenses can make lens-fitting efficient, they added.

The scientists reached their conclusions by conducting a retrospective case series involving 346 eyes in 212 patients from 2006 to 2011. They reviewed medical records and analysed a survey of patients who had undergone the scleral lens-fitting process to measure therapeutic outcome, VA improvement and fitting efficiency.

The lens-fitting process was successful in 115 participants (188 eyes) of the 212 they studied. All but 2 of them experienced improved comfort, a protected ocular surface or keratopathy resolution as relevant to their therapeutic goals.

Participants also saw improved VA, which with lens wear went from 0.32±0.37 logarithm of the minimal angle of resolution (logMAR) with habitual correction to 0.12±0.19 logMAR (20/42 to 20/26 Snellen) (P

Patients most often were fitted for scleral lenses because of undifferentiated OSD, exposure keratopathy or neurotrophic keratopathy after having tried other interventions (average 3.2, range, 0–8). The fitting took an average of 3 visits (range, 2–6) with 1.4 lenses per eye, on average (range, 1–4).

Complications arose in 3 patients while they were wearing the lenses, but the complications resolved without VA loss, and the patients were able to resume wearing the lenses.

The study was published in Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.